NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER 2) Negative Breast Cancer Patients

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+, AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with TNBC must have tumors that are also AR+; Patients must be within 1 year following completion of curative-intent chemotherapy
Exclusions: Patients with active brain metastases or leptomeningeal metastases- see trial for details; Patients who have received more than 1 line of chemotherapy in the metastatic setting; Prior therapy with an anti-PD-1, -PD-L1, -PD-L, or- CTLA-4 agent or with bicalutamide, enzalutamide, or any other AR blocker

Comments are closed.

Up ↑